Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 5/20 | 0.61 |
| ▸ | PLK2 | Q9NYY3 | 5/20 | 0.61 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.45 |
| ▸ | PRKDC | P78527 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.36 |
| ▸ | MTOR | P42345 | 3/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6844827 | 0.95 | PLK1 (0.60) | PLK1PLK2PLK3PRKDCPIK3CA | |
| SCHEMBL6844759 | 0.84 | PLK1 (0.47) | PLK1PLK2PLK3PRKDCPIK3CA | |
| SCHEMBL6844665 | 0.83 | PLK1 (0.47) | PLK1PLK2PLK3PRKDCPIK3CA | |
| SCHEMBL6844840 | 0.81 | PLK1 (0.51) | PLK1PLK2PLK3PIK3CAMTOR | |
| SCHEMBL6844664 | 0.78 | PLK1 (0.52) | PLK1PLK2PLK3 | |
| SCHEMBL2048108 | 0.76 | PLK2 (1.00) | PLK1PLK2PLK3 | |
| SCHEMBL12277533 | 0.76 | PLK2 (1.00) | PLK1PLK2PLK3 | |
| SCHEMBL6911355 | 0.72 | PLK1 (0.50) | PLK1PLK2PLK3 | |
| SCHEMBL2049281 | 0.72 | PLK1 (1.00) | PLK1PLK2PLK3 | |
| SCHEMBL2049275 | 0.72 | PLK1 (1.00) | PLK1PLK2PLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011079118-A1 | PTERIDINONES AS INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC (US) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011079114-A1 | PTERIDINONES AS INHIBITORS OF POLO - LIKE KINASE | ELAN PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | WO | disclosed |